Nanobiotix Announces EUR 2.8 Million Grant From bpifrance to Accelerate Development of NBTXR3 in a Third New Indication


Through ETPN (European Technology Platform of Nanomedicine), Nanobiotix Is Driving Nanomedicine in Europe and Is Now Involved in the First Nanomedicine Consortium in France With the launch of NICE Project
201306047919620PARIS–(Marketwired – Jul 3, 2013) – NANOBIOTIX (EURONEXT PARIS: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today it has secured c.EUR 9 million in funding from bpifrance (formerly OSEO) of which EUR 2.8 million is directly attributable to the Company. This grant, awarded through bpifrance’s Strategic Industrial Innovation (ISI) program, will accelerate the clinical and industrial development of the Company’s lead product NBTXR3 in a new indication, liver cancer (hepatocellular carcinoma). Liver cancer is a major health problem that causes one of the greatest number of deaths each year worldwide, c.695,000 deaths per annum.

This grant supports the launch of NICE (Nano Innovation for CancEr), the first consortium of nanomedicine stakeholders in France focused on characterization and industrialization aspects. The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France (www.medicen.org).

Consisting of five public and private partners, the NICE consortium includes partners with in depth expertise in the field of nanomedicine. Its mission is to build a platform to accelerate the development and industrialization of nanomedicine in France by capitalizing on the strong and complementary expertise of each partner.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for advanced soft tissue sarcoma and has received authorization from the French Medicine Agency, ANSM, to start a second clinical trial in patients with locally advanced cancers of the oral cavity or oropharynx (head and neck cancer). NBTXR3 will benefit fully from this platform of expertise and funding received from bpifrance by being able to accelerate its clinical development. The purpose of this project is the start of a new Phase I clinical study with NBTXR3 in patients with primary liver cancer.

Watch the Video from Nanobiotix here:

http://www.youtube.com/watch?v=kxSX6YJTS2I&feature=share&list=PL9C30814198614279

In addition to Nanobiotix, the consortium includes BioAlliance Pharma, leader of the consortium which is developing Livatag®, a doxorubicin nanoparticle currently in Phase III clinical trial for treatment of primary liver cancer; CEA-Leti, the developer of cancer-detecting nanoparticles based on Leti’s Lipidots® platform; DBI, a company specialized in the production of nanomedicine pharmaceutical products and the Institut Galien Paris Sud (University Paris Sud/CNRS), which has an academic-excellence team specialized in nanoparticle research.

Today, nanomedicine is considered as one of the major growth drivers of the global pharmaceutical industry and it is essential that the industry is structured at the local level to be competitive,” said Laurent Levy, CEO of Nanobiotix. “In turn, Nanobiotix will benefit from the consortium in two ways; if the sector is structured right to be able to accelerate the development and industrialization of products, and in the development of a new indication of NBTX3 which will help patients and build shareholder value.”

About BPIFRANCE’s Strategic Industrial Innovation (ISI) program

The Strategic Industrial Innovation program promotes the emergence of European champions. It supports ambitious, innovative collaborative projects through to industrialization, driven by innovative medium-sized companies (less than 5000 employees) and small businesses (less than 250 employees). These highly promising projects are aimed at the commercialization of products which result from technological breakthroughs and which not be possible without fostering measures from the public sector. Funding is generally in the EUR 3-10 million range, as grants-in aid and loans which are repayable if the project is a success.

About NANOXRAY

Nanobiotix’s first-in-class, proprietary technology called NanoXray is at the forefront of a new era of nanomedicine, where nanoparticles are not just a vehicle for targeted drug delivery, but have become the principal active element. The NanoXray technology is based on the physical properties of hafnium-oxide nanoparticles and is used to enhance the efficacy of radiotherapy treatment for a variety of cancer indications.

Nanoparticles are designed to enter tumor cells and, upon activation by a standard dose of radiation, they emit large amounts of electrons resulting in the generation of free radicals that destroy cancer cells (the same mode of action than radiotherapy but largely amplified). Nanoparticle-enhanced radiotherapy therefore amplifies the lethal dose of energy locally within the tumor without changing the effect of the dose passing through surrounding healthy tissues.

By changing the coating of the nanoparticles, Nanobiotix is developing three different products that can be administered either by direct injection into the tumor (NBTXR3), intravenous injection (NBTX-IV) or topical application to fill tumor cavities after surgery (NBTX-TOPO). The product applied will depend on type of tumor and the patient’s specific clinical needs. NanoXray products are classified as a medical device in Europe and as a drug in the US. They are compatible with current radiotherapy methods with respect to equipment and protocols, as well as with older radiotherapy equipment or any radiation-based therapy.

About NANOBIOTIX

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. The Company is based in Paris, France.

Laurent Levy, CEO and co-founder of Nanobiotix, is the Vice-President of the European Technology Platform of Nanomedicine (ETPN).

For more information, please visit www.nanobiotix.com

Press release (PDF): http://hugin.info/157012/R/1714109/569130.pdf

International Nanotechnology conference 2013: Dubai


QDOTS imagesCAKXSY1K 8SETCOR Nanotech Dubai 2013 brings together leading scientists, researchers, engineers, practitioners, technology developers and policy makers in nanotechnology to exchange information on their latest research progress, innovation and business opportunities. It’s among the most important events in terms of international regulatory policies and it’s opened to the participation of private companies. It’s unique venue for companies to promote equipment and technology.
The conference covers all frontier topics in nanotechnology. The conference includes plenary lectures and invited talks by eminent personalities from around the world in addition to contributed papers both oral and poster presentations.
SETCOR Nanotech Dubai 2103 conference organizing committee is looking forward to welcoming you in Dubai- United Arab Emirates.
Conference Scope

Themes of the 3 days event will be as follow:

  • Advanced Materials
  • Nanoscale Electronics
  • Nanotech in Life Sciences & Medicine
  • Energy & Environment
  • Fabrication, Characterization & Tools
  • Nanotechnology safety
  • Nano Application

 

 

Keynote Speakers

Speakers

1369167059_Andrea Ferrari.png

Prof. Andrea C. Ferrari

Cambridge Graphene Centre, Engineering Department, University of Cambridge– UK

1369167274_Bouzis Menaa.png

Dr. Bouzid Menaa

Fluorotronics, Inc, San Diego, CA– USA

1369167289_Erich Sackmann.png

Prof. Erich Sackmann

Institute of Molecular and Cellular Biophysics, Technische Universitat Munchen- Germany

1369167305_Farzaneh Arefi-Khonsari.jpg

Prof. Farzaneh Arefi-Khonsari

University of Pierre & Marie Curie, Paris, France

1369167327_Adnane Abdelghani.jpg

Prof. Adnane Abdelghani

National Institute of Applied Science and Technology, Tunis-Tunisia

1369167596_Axel Lorke.png

Prof. Axel Lorke

Faculty of Physics and CeNIDE, University of Duisburg-Essen-Germany

1369167616_Jackie Ying.jpg

Prof. Jackie Ying

Executive Director, Institute of Bio-engineering and Nanotechnology, Singapore.

1370640110_Dr Vasco Teixeira.png

Dr. Vasco Teixeira

Associate Professor in Materials Physics, University of Minho

Nanosolar CEO, Eugenia Corrales


QDOTS imagesCAKXSY1K 8A new CEO at the CIGS thin film solar firm

Eric Wesoff: January 19, 2012

 

Last week we reported that Brian Stone, a VP at Nanosolar, had left the firm.

Today, the personnel shifts continued at the CIGS thin film solar vendor.

Geoff Tate, CEO for about two years, has been replaced by Eugenia Corrales, who will assume the position immediately.

According to a press release, Tate recruited Corrales in May 2010 to serve as the EVP of engineering and operations. The release continues, “Ms. Corrales held a number of executive positions, including several years as a Vice President at Cisco, where she ran all of Product Operations for Cisco-branded products. She was previously responsible for Manufacturing Operations of $7B in router, switching and optical product revenue.  Prior to Cisco, Corrales spent 11 years in engineering and R&D management at HP. Prior to joining Nanosolar, she was founder and VP of engineering of two cleantech startups. She holds a bachelor’s degree in physics from Grinnell College and a master’s in mechanical engineering from Stanford University.”

Nanosolar has had a history of technical and commercial promises, most recently these relating to cost:

  • Below $1.00 per watt factory cost by the end of 2011
  • Low $0.80s or high $0.70s per watt by late 2012
  • In the $0.60s in 2013
  • Below $0.60 per watt in 2014

Nanosolar produced 2.5 megawatts of panels in 2010. The firm has only shipped a cumulative total of 10 megawatts in its history.

The firm has suggested that it will ship megawatts measuring in the “triple digits” in 2012. Cell production capacity was to be 115 megawatts at the end of 2011, and the next step jumps the firm to 250 megawatts of cell capacity at the San Jose facility. Panel assembly is performed at Nanosolar’s factory in Luckenwalde, Germany.
The firm is shipping 10-percent-efficiency panels today with a target of 12 percent efficiency this year. Expectations are for 13 percent in 2013 and 14 percent in 2014. However, attaining a 4-percentage-point increase in efficiency in the space of four years would be an unprecedented feat never before achieved by any solar firm.

The company is focused solely on utility-scale deployments. Its large utility-size panels are currently rated at 200 watts, with additional output gains expected as efficiency rises.

Nanosolar also announced that it has signed long-term supply agreements for up to one gigawatt of PV panels with Belectric of Kolitzheim, Germany; EDF Energies Nouvelles of Paris, France; and Plain Energy of Munich, Germany.

Take that “long-term supply agreement” lingo with a grain of salt, however. These contracts are not binding, are not take-or-pay, and are predicated on Nanosolar’s ability to achieve its cost and efficiency targets as promised. Still, although those agreements don’t translate as real backlog, they do translate to patient customers who appear willing to work with Nanosolar. Nanosolar, as a new supplier without a field performance track record, employs module warranty insurance to help financiers and customers feel comfortable and improve the firm’s bankability.

Ed Gunther reported on a number of other promises made by the company at a recent solar event.

An investor in Nanosolar I spoke with recently still maintains that Nanosolar is one of the few firms that can give First Solar and the Chinese c-Si vendors a run for their money.

Nanosolar will also have to raise large amounts of funding in the short term, a difficult situation in the post-Solyndra CIGS era and a challenging task for the new CEO.

http://www.greentechmedia.com/articles/read/Longtime-Nanosolar-Spin-Doctor-Brian-Stone-Departs-Firm/